Pretargeted PET of osteodestructive lesions in dogs Journal Article
| Authors: | Maitz, C. A.; Delaney, S.; Cook, B. E.; Genady, A. R.; Hoerres, R.; Kuchuk, M.; Makris, G.; Valliant, J. F.; Sadeghi, S.; Lewis, J. S.; Hennkens, H. M.; Bryan, J. N.; Zeglis, B. M. |
| Article Title: | Pretargeted PET of osteodestructive lesions in dogs |
| Abstract: | The last decade has witnessed the creation of a highly effective approach to in vivo pretargeting based on the inverse electron demand Diels-Alder (IEDDA) click ligation between tetrazine (Tz) and trans-cyclooctene (TCO). Despite the steady progression of this technology toward the clinic, concerns have persisted regarding whether this in vivo chemistry will work in humans given their larger size and blood volume. In this work, we describe the use of a 64Cu-labeled Tz radioligand ([64Cu]Cu-SarAr-Tz) and a TCO-bearing bisphosphonate (TCO-BP) for the pretargeted positron emission tomography (PET) imaging of osteodestructive lesions in a large animal model: companion dogs. First, in a small animal pilot study, healthy mice were injected with TCO-BP followed after 1 or 6 h by [64Cu]Cu-SarAr-Tz. PET images were collected 1, 6, and 24 h after the administration of [64Cu]Cu-SarAr-Tz, revealing that this approach produced high activity concentrations in the bone (>20 and >15%ID/g in the femur and humerus, respectively, at 24 h post injection) as well as high target-to-background contrast. Subsequently, companion dogs (n = 5) presenting with osteodestructive lesions were administered TCO-BP (5 or 10 mg/kg) followed 1 h later by [64Cu]Cu-SarAr-Tz (2.2-7.3 mCi; 81.4-270.1 MBq). PET scans were collected for each dog 4 h after the administration of the radioligand, and SUV values for the osteodestructive lesions, healthy bones, and kidneys were determined. In these animals, pretargeted PET clearly delineated healthy bone and produced very high activity concentrations in osteodestructive lesions. Low levels of uptake were observed in all healthy organs except for the kidneys and bladder due to the renal excretion of excess radioligand. Ultimately, this work not only illustrates that pretargeted PET with TCO-BP and [64Cu]Cu-SarAr-Tz is an effective tool for the visualization of osteodestructive lesions but also demonstrates for the first time that in vivo pretargeting based on IEDDA click chemistry is feasible in large animals. © 2022 American Chemical Society. |
| Keywords: | osteosarcoma; positron emission tomography; radiopharmaceuticals; mouse; animal; animals; mice; cell line, tumor; pilot study; pilot projects; dog; dogs; tumor cell line; positron-emission tomography; radiopharmaceutical agent; click chemistry; bisphosphonate; procedures; canines; cyclooctanes; humans; human; tetrazine; trans-cyclooctene; copper-64; in vivo pretargeting; cyclooctane derivative |
| Journal Title: | Molecular Pharmaceutics |
| Volume: | 19 |
| Issue: | 9 |
| ISSN: | 1543-8384 |
| Publisher: | American Chemical Society |
| Date Published: | 2022-09-05 |
| Start Page: | 3153 |
| End Page: | 3162 |
| Language: | English |
| DOI: | 10.1021/acs.molpharmaceut.2c00220 |
| PUBMED: | 35635337 |
| PROVIDER: | scopus |
| PMCID: | PMC10316029 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 October 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work